Zealand Pharma A-S für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A0YJW7 / ISIN: DK0060257814

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Zealand Pharma A-S

31.03.25		Total number of shares and voting rights in Zealand Pharma as of March 31, 2025 (GlobeNewswire)
27.03.25		Resolutions from Zealand Pharma's Annual General Meeting 2025 (GlobeNewswire)
25.03.25		Zealand Pharma major shareholder announcement: Van Herk Investments B.V. (GlobeNewswire)
20.03.25		Zealand Pharma increases its share capital as a result of the exercise of employee warrants (GlobeNewswire)
20.02.25		Zealand Pharma convenes its Annual General Meeting 2025 (GlobeNewswire)
20.02.25		Zealand Pharma Announces Financial Results for the Full Year 2024 (GlobeNewswire)
13.01.25		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
25.12.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
25.12.24		Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. (GlobeNewswire)
11.11.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
07.11.24		Zealand Pharma Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
09.10.24		Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism (GlobeNewswire)
08.10.24		Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide (GlobeNewswire)
30.09.24		Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 (GlobeNewswire)
12.09.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
09.09.24		Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide (GlobeNewswire)
30.08.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
30.08.24		Total number of shares and voting rights in Zealand Pharma on August 30, 2024 (GlobeNewswire)
22.08.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
16.08.24		Zealand Pharma major shareholder announcement: Bank of America Corporation (GlobeNewswire)
15.08.24		Zealand Pharma Announces Financial Results for the First Half of 2024 (GlobeNewswire)
28.06.24		Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
28.06.24		Total number of shares and voting rights in Zealand Pharma at June 28, 2024 (GlobeNewswire)
28.06.24		Zealand Pharma completes registration of capital increase (GlobeNewswire)
26.06.24		Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion (GlobeNewswire)
25.06.24		Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion (GlobeNewswire)
25.06.24		Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion (GlobeNewswire)
20.06.24		Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide (GlobeNewswire)
13.06.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
07.06.24		Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis (GlobeNewswire)
06.06.24		Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL (GlobeNewswire)
29.05.24		Zealand Pharma major shareholder announcement: Polar Capital (GlobeNewswire)
23.05.24		Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide (GlobeNewswire)
16.05.24		Zealand Pharma Announces Financial Results for the First Quarter of 2024 (GlobeNewswire)
12.05.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
19.04.24		Correction to Company announcement – No. 23 / 2024 (GlobeNewswire)
19.04.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
19.04.24		Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 (GlobeNewswire)
31.03.24		Total number of shares and voting rights in Zealand Pharma at March 31, 2024 (GlobeNewswire)
26.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
26.03.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
21.03.24		Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
20.03.24		Zealand Pharma's Annual General Meeting 2024 (GlobeNewswire)
19.03.24		Zealand Pharma major shareholder announcement: Polar Capital (GlobeNewswire)
19.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
13.03.24		New Employee Elected Directors to the Board of Zealand Pharma A/S (GlobeNewswire)
08.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
05.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
05.03.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
27.02.24		Zealand Pharma convenes its Annual General Meeting 2024 (GlobeNewswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Trumps neues Zollpaket: ATX und DAX zum Handelsende mit herben Verlusten -- US-Börsen schließen tiefrot -- China-Börsen fallen letztlich - Nikkei stürzt ab

Nach Goldpreis-Rally: Darum erwarten Experten auch einen starken Anstieg bei Silber

Trumps Zollpaket sorgt für Börsenturbulenzen: NVIDIA, Tesla und andere Magnificent 7-Aktien fallen

Zoll-Turbulenzen: Aktien von Deutsche Bank und Commerzbank verlieren, Immobilienwerte steigen

JENOPTIK-Aktie tiefrot: UBS stuft JENOPTIK ab und senkt Kursziel drastisch

Sichere Aktien im Handelskrieg: Diese Investments könnten sich lohnen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	06.04.2025 20:03
Kaufwert:	EUR
	Hinzufügen Speichern

Zealand Pharma A-S Aktie

WKN DE: A0YJW7 / ISIN: DK0060257814

Nachrichten zu Zealand Pharma A-S

Newssuche

Meistgelesene Nachrichten